MENU
+Compare
SUPN
Stock ticker: NASDAQ
AS OF
Apr 3, 04:59 PM (EDT)
Price
$32.50
Change
-$0.32 (-0.98%)
Capitalization
1.84B

SUPN stock forecast, quote, news & analysis

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company... Show more

SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SUPN with price predictions
Apr 02, 2025

SUPN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SUPN turned positive on March 14, 2025. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SUPN's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 02, 2025. You may want to consider a long position or call options on SUPN as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in of 321 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where SUPN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SUPN entered a downward trend on March 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.992) is normal, around the industry mean (60.901). SUPN's P/E Ratio (1677.000) is considerably higher than the industry average of (90.174). SUPN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (3.065) is also within normal values, averaging (20.092).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 3.67B. The market cap for tickers in the group ranges from 246 to 77.48B. ZTS holds the highest valuation in this group at 77.48B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -3%. For the same Industry, the average monthly price growth was 65%, and the average quarterly price growth was -10%. MSTH experienced the highest price growth at 139%, while PNXP experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -72%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was 115%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 67
Price Growth Rating: 65
SMR Rating: 84
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer for the treatment of central nervous system

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
9715 Key West Avenue
Phone
+1 301 838-2500
Employees
652
Web
https://www.supernus.com